Short answer
Zymeworks Inc. (ZYME) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 8.01 (Other Events), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Second 2026 Share Repurchase Program announced, signaling continued capital return to shareholders.
Zymeworks Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Second 2026 Share Repurchase Program announced, signaling continued capital return to shareholders
- Potential reduction in shares outstanding, supporting per-share metrics if repurchases are executed
- Program terms and authorization size require review of Exhibit 99.1
Item 8.01 · Other Events
- New $200.0 million share repurchase authorization through 2028
- Initial 2026 program completed after $125.0 million authorization
- Capital return signals management confidence and may reduce shares outstanding
- Repurchases could support per-share metrics while reducing cash available for operations or acquisitions
Item EX-99.1 · Exhibit EX-99.1
- $200 million repurchase authorization through 2028, with approximately $140 million currently expected to be deployed
- Program launch before year-end 2026, following completion of the initial $125 million authorization
- Approximately 68.7 million shares outstanding as of November 11, 2026, creating potential for meaningful share-count reduction
- Funding relies on existing cash plus expected $55 million Roche upfront fees and potential $100 million TRELEGY milestone
- Capital allocation balanced among R&D, selective M&A and buybacks, signaling confidence in cash generation but reducing funds available for acquisitions or development
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Zymeworks Inc. 8-K filings
Get the next ZYME 8-K as it lands
Follow ZYME for push alerts, or ask the research agent what this filing means.